Drug – bio-affecting and body treating compositions – Designated organic active ingredient containing – Heterocyclic carbon compounds containing a hetero ring...
Patent
1997-12-19
1999-10-12
Bernhardt, Emily
Drug, bio-affecting and body treating compositions
Designated organic active ingredient containing
Heterocyclic carbon compounds containing a hetero ring...
514254, 514255, 514318, 514320, 514323, 514324, 544360, 544363, 544373, 544376, 544394, 546194, 546196, 546200, 546201, 546202, A61K 31495, A61K 31445, C07D295096, C07D40104
Patent
active
059655607
DESCRIPTION:
BRIEF SUMMARY
BACKGROUND OF THE INVENTION
The present invention relates to novel substituted piperazines and piperidines and derivatives thereof useful as pharmaceutical agents, to methods for their production, to pharmaceutical compositions which include these compounds and a pharmaceutically acceptable carrier, and to pharmaceutical methods of treatment. The novel compounds of the present invention are central nervous system agents. More particularly, the novel compounds of the present invention are dopamine antagonists.
Dopamine (DA) D2 antagonists are established as antipsychotic agents. Undesired consequences of DA D2 antagonism are extrapyramidal side effects and tardive dyskinesia. More recently, the DA D4 receptor has been identified as having a possible role in schizophrenia. The atypical antipsychotic drug clozapine has a tenfold higher affinity for the DA D4 receptor than the D2 (Van Tol H. H. J., Bunzow J. R., Guan H. -C., et al., "Cloning of a human dopamine D4 receptor gene with high affinity for the antipsychotic clozapine." Nature, 1991;350:614-619) and is notable for its lack of extrapyramidal side effects and tardive dyskinesia. The levels of mRNA for the D4 receptor are much higher in the frontal cortex and limbic region, which are associated with cognitive and emotional function, than in the striatum, which is associated with movement (Van Tol, et al., supra, 1991). In addition, Seeman P., Guan H. -C., and Van Tol H. H. M., "Dopamine D4 receptors elevated in schizophrenia," Nature, 1993;365:441-445 has reported a sixfold increase of the D4 recept or number in postmortem specimens from patients with schizophrenia compared to controls.
The compounds of the present invention were shown to selectively bind to the DA D4 receptor while having weak affinity for the DA D2 and DA D3 receptors.
A series of piperazines represented by the Formula I ##STR1## A=CO, COCH.sub.2, COCH.sub.2 CH.sub.2, CH(OH)CH.sub.2 CH.sub.2, COCH.sub.2 CH.sub.2 CH.sub.2, or CH(OH)CH.sub.2 CH.sub.2 CH.sub.2 p-t-butylbenzyl, phenethyl, C.sub.6 H.sub.5, o- or p-chlorophenyl, o-, m-, or p-methoxyphenyl, o-, m-, or p-tolyl, 2,6-xylyl, 2-pyridyl, 2-pyrimidyl, or 2-thiazolyl are disclosed by Petigara R. B., et al., Journal of Medicinal Chemistry, 1968;11:332-336 as central nervous system depressants.
A series of arylpiperazines represented by the Formula I ##STR2## wherein R is hydrogen, trifluoromethyl, hydroxy, nitro, halogen, lower alkyl, or lower alkoxy; and thereof are disclosed in United Kingdom Published Patent Application GB 2,057,441A as having circulation-enhancing activity.
The compounds of the present invention, unlike the compounds disclosed in Petigara R. B., et al., supra, (1968) and United Kingdom Published Patent Application GB 2,057,441A, interact selectively with the DA D4 receptor. Thus, the compounds of the present invention are DA D4 selective antagonists which are useful in the treatment of psychosis such as schizophrenia without the extrapyramidal side effects associated with an agent that interacts with the DA D2 receptor.
SUMMARY OF THE INVENTION
Accordingly, a first aspect of the present invention is a compound of Formula I ##STR3## wherein X is N or CH; and R is aryl or heteroaryl; or a pharmaceutically acceptable acid additional salt thereof;
phenyl monosubstituted by
phenyl disubstituted by lower alkyl, or phenyl trisubstituted by lower alkoxy.
A second aspect of the present invention is a compound of Formula Ia ##STR4## wherein X is N or CH; and R is aryl or heteroaryl; or a pharmaceutically acceptable acid addition salt thereof; with the following provisos:
(a) that when X is N or CH, and R is aryl, aryl is not phenyl, or
(b) that when X is N and R is heteroaryl, heteroaryl is not 2-, 3-, or 4-pyridinyl.
As dopamine antagonists, the compounds of Formula I and Formula Ia are antipsychotic agents useful for treating psychoses such as schizophrenia.
A still further embodiment of the present invention is a pharmaceutical composition for administering an effective amount of a compound of Formula I or Formula I
REFERENCES:
patent: 4370329 (1983-01-01), Scherm et al.
patent: 4370330 (1983-01-01), Scherm et al.
patent: 4673675 (1987-06-01), Robba et al.
Gazi et al., British Journal of Pharmacology, 124, pp. 889-896, 1998.
TenBrink etr al.,Journal of Medicinal Chemistry, vol. 39, pp. 2435-2437, 1996.
Petrigara et al, J. Med. Chem. 11, pp. 332-336 (1968).
Prasad et al, J. Med. Chem. 11, pp. 1144-1150 (1968).
Gootjes et al, Arzneimittel-Forschung 17(9), pp. 1145-1149 (1967).
Reynolds, Drugs, 51, pp. 7-11 (1996).
Rulagowski et al, Current Pharmaceutical Design 3, pp. 355-366 (1997).
Glase Shelly A.
Purchase Terri S.
Wise Lawrence D.
Bernhardt Emily
Tinney Francis J.
Warner-Lambert & Company
LandOfFree
Substituted piperazines and piperidines as central nervous syste does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Substituted piperazines and piperidines as central nervous syste, we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Substituted piperazines and piperidines as central nervous syste will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-652699